Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 312Pancreatic Neoplasms 176Carcinoma, Hepatocellular 117Stomach Neoplasms 114Esophageal Neoplasms 83Carcinoma, Non-Small-Cell Lung 82Colonic Neoplasms 81Rectal Neoplasms 73Breast Neoplasms 73Ovarian Neoplasms 61Neoplasm Metastasis 60Lung Neoplasms 57Neoplasms 55Cholangiocarcinoma 53Gastrointestinal Neoplasms 45Melanoma 44Liver Neoplasms 43Prostatic Neoplasms 40Endometrial Neoplasms 33Squamous Cell Carcinoma of Head and Neck 32Sarcoma 32Biliary Tract Neoplasms 32Carcinoma, Renal Cell 30Esophageal Squamous Cell Carcinoma 28Uterine Cervical Neoplasms 26Head and Neck Neoplasms 24Urinary Bladder Neoplasms 23Adenocarcinoma Of Esophagus 23Small Cell Lung Carcinoma 20Triple Negative Breast Neoplasms 17

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Gastrointestinal × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡